Overall, these data suggest that parenteral treatment of trehalose is effective against HFD-induced obesity although no additive metabolic benefits are realized in the setting of elevated trehalose levels from Treh inhibition. The gene discussed is TREH; the disease is obesity due to melanocortin 4 receptor deficiency.